Citius Pharmaceuticals Inc (CTXR)
0.5219
0.00 (0.00%)
USD |
NASDAQ |
Sep 27, 16:00
0.5218
0.00 (0.00%)
After-Hours: 20:00
Citius Pharmaceuticals SG&A Expense (Annual): 21.91M for Sept. 30, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| September 30, 2023 | 21.91M |
| September 30, 2022 | 15.66M |
| September 30, 2021 | 11.29M |
| September 30, 2020 | 8.898M |
| September 30, 2019 | 7.002M |
| September 30, 2018 | 7.226M |
| Date | Value |
|---|---|
| September 30, 2017 | 7.050M |
| September 30, 2016 | 4.516M |
| September 30, 2015 | 1.433M |
| September 30, 2013 | 0.0281M |
| September 30, 2012 | 0.0196M |
| September 30, 2011 | 0.0256M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
7.002M
Minimum
2019
21.91M
Maximum
2023
12.95M
Average
11.29M
Median
2021
SG&A Expense (Annual) Benchmarks
| Agilent Technologies Inc | 1.634B |
| Seelos Therapeutics Inc | 12.58M |
| Cara Therapeutics Inc | 27.65M |
| Moleculin Biotech Inc | 10.02M |
| Citius Oncology Inc | -- |